Quantcast

Bruckner Oncology Presents at the AACR’s 2014 Annual Meeting

April 8, 2014

Metronomic algorithms for targeted therapy to improve value of response and “failed drugs” for “resistant women’s cancers”

NEW YORK, April 8, 2014 /PRNewswire/ — The following will be presented this week at the annual meeting of the American Association of Cancer Research, San Diego.

Dr Howard Bruckner will present accumulating evidence describing a novel successful treatment for patients with resistant ovarian cancer. Low dose chemotherapy as cores, selected drug combinations, safely combined with targeted antiangiogenic or anti growth factor EGF drugs can produce response rates of 80-90% with clinical benefit. This is the fourth class of tumors for which Dr Bruckner’s cores plus targeted therapy (CPTT) provide a second chance for important drugs to achieve better tumor reduction after previously administered chemotherapy, at higher dosages and sometimes the targeted drug as well, had failed or is no longer effective. Cores plus targeted therapy in effect reverse the tumors resistance to drugs and increase the number of options with approved drugs available to patients.

Analyses of quality and duration of tumor regression in this heterogeneous group of patients with several urgent needs for which there are no current good solutions, identified promising test worthy treatment strategies, sometimes successful solutions for these common complications of ovarian cancer. CPTT can often reverse (even life threatening) symptoms and provide late, last resort or possibly pre hospice patients with options, after all conventional high dose options failed or become unsafe. The low doses have reduced toxicity and sometimes can spare patients from severe nerve damage, fatigue, weight loss and adverse events which require hospitalization.

Both low doses and targeted therapy are neither adequate or cost effective as a substitute for first standard treatment for patients with ideal resections or for non drug resistant tumors. Cores are test worthy for integration, for specific early and late failures of standard treatment’s efficacy, tolerability or safety; these are characterized as “niche applications” for reversing many manifestations of resistance without any promising or conventional treatments.

The ability to deploy more drugs which assist one another safely increase the chances to provide drugs with their ideal partners. This predicts beneficial economic impact for more cost effective individual care.

The presentation also describes use of cores for fifth and sixth refractory diseases, uterine cancers and sarcomas.

The presenter, Howard W. Bruckner MD, a former professor, author of 150 plus publications and 200 more abstracts, was the first to describe the use of platinum for ovarian cancer (ASCO) and high dose platinum.

Contact information:
Howard Bruckner, MD
Director of The MZB Foundation for Cancer Research
BrucknerOncology@gmail.com;
www.BrucknerOncology.com;
212-590-5838;718-732-4050

SOURCE Bruckner Oncology


Source: PR Newswire



comments powered by Disqus